Boehringer Ingelheim Pharma GmbH & Co. KG

"EFFECTIVE LUNG AGE" IN SUBJECTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) IN THE SENSCIS TRIAL (2022) Maher T, Bourdin A, Volkmann E, Vettori S, Distler J, Alves M, Stock C, Distler O Conference contribution Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project) (2022) Bernabei R, Landi F, Calvani R, Cesari M, Del Signore S, Anker SD, Bejuit R, et al. Journal article Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment (2022) Bruni C, Heidenreich S, Duenas A, Hoffmann-Vold AM, Gabrielli A, Allanore Y, Chatelus E, et al. Journal article Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial (2022) Matteson EL, Kelly C, Distler J, Hoffmann-Vold AM, Seibold JR, Mittoo S, Dellaripa PF, et al. Journal article Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry. (2022) Lip GYH, Kotalczyk A, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, et al. Journal article Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry. (2022) Lip GYH, Kotalczyk A, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, et al. Journal article, Erratum Deletion of the diabetes candidate gene Slc16a13 in mice attenuates diet-induced ectopic lipid accumulation and insulin resistance (2021) Schumann T, König J, von Loeffelholz C, Vatner DF, Zhang D, Perry RJ, Bernier M, et al. Journal article Immunocompetent cancer-on-chip models to assess immuno-oncology therapy (2021) Maulana TI, Kromidas E, Wallstabe L, Cipriano M, Alb M, Zaupa C, Hudecek M, et al. Journal article, Review article PATIENT PREFERENCES, TRADE-OFFS AND ACCEPTABLE RISKS IN THE TREATMENT OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: A STEP TOWARDS SHARED DECISION-MAKING (2021) Bruni C, Heidenreich S, Duenas A, Hoffmann-Vold AM, Gabrielli A, Allanore Y, Chatelus E, et al. Conference contribution DECLINE IN FORCED VITAL CAPACITY (FVC) IN SUBJECTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) IN THE SENSCIS TRIAL VERSUS HYPOTHETICAL REFERENCE SUBJECTS WITHOUT LUNG DISEASE (2021) Maher T, Bourdin A, Volkmann E, Vettori S, Distler J, Alves M, Stock C, Distler O Conference contribution